CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
December 02, 2020
 The PR22 (ANZUP 1801) study DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer has been centrally activated in Canada. Read More |
 CCTG is sends a big congratulations to all of the TMIST participating centres in Canada. Just twelve weeks later after 4000 subjects were accrued in late August, we have reached another BIG milestone for the MAC22 study: more than 5000 are enrolled in Canada!
|
CCTG is recruiting for a Patient Representative Volunteer RolePublished: December 02, 2020Category: Group updates  The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth). Read More |
CCTG Remote Audit and Monitoring Working Group (RAM WG) ActivePublished: December 02, 2020Category: Group updates  The COVID 19 pandemic increased focus on mechanisms to oversee clinical studies remotely in order to limit travel and number of visitors to clinical trial sites. The Canadian Cancer Trials Group (CCTG) created the Remote Auditing and Monitoring Working Group (RAM WG) this past summer to support CCTG member centres navigate new ways of working with respect to remote monitoring and auditing practices. Read More |
Congrats to Dr Lhereux who has recently been awaded a CCS research grantPublished: December 02, 2020Category: Group updates  Congratulations from CCTG! The Canadian Cancer Society (CCS) has funded its first research grant focused specifically on rare and aggressive uterine cancers, a critical first step to better outcomes for people with these cancers to Dr Stephanie Lheureux. |
 MA21 - Anthracyclines are frequently used in adjuvant treatment for early-stage breast cancer (ESBC). The purpose of this study was to evaluate cardiotoxic effects in the first five years after treatment with different anthracycline-based regimens.
ALC3 - Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT.
|
November 18, 2020
 CCTG would like to extend congratulations to Dr. Kelvin Chan the recipient of the 2020 Dr. Maurice McGregor Award from Canadian Agency for Drugs and Technologies in Health (CADTH). The Dr. Maurice McGregor Award, honours rising stars early in their careers. Read More |
Dr. Tony Reiman CCS Research Chair, University of New BrunswickPublished: November 18, 2020Category:  Congratulations to our CCTG Hematologic Disease Site Chair, Dr. Tony Reiman, who has been successfully reappointed as the Canadian Cancer Society Research Chair at the University of New Brunswick. Read More |